EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 894 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR What People With Breast Cancer and Survivors Should Know About Exercising... October 4, 2022 Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034... June 3, 2026 Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... September 26, 2019 Load more HOT NEWS Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in... A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... Father Dances With Joy After Learning His Son Is Cancer Free New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of...
